Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

Levetiracetam, a relatively recent addition to antiepileptic medications, is known for its broad-spectrum efficacy in treating partial and generalized tonic-clonic seizures in individuals of all age groups. Despite its favourable tolerability profile, rare instances of psychiatric side effects have been reported. This case study presents a rare occurrence of significant behavioural changes attributed to levetiracetam in a young female patient.

Case History

A 40-year-old woman with a long-standing history of epilepsy, well-managed with medication, presented with abrupt-onset behavioural changes, including irritability, aggression, crying spells, insomnia, increased talkativeness, and screaming. Notably, these behavioural changes were unrelated to seizure activity and emerged without precedent. A dose reduction of levetiracetam was also attempted, which proved ineffective in mitigating her symptoms.

Conclusion

Consequently, the drug was discontinued, resulting in the resolution of the behavioural symptoms. This case highlights levetiracetam as the likely causative factor behind the observed significant behavioural changes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863285429240326172920
2025-05-01
2025-10-03

  • From This Site

    /content/journals/cds/10.2174/0115748863285429240326172920
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. OgunsakinO. TumentaT. Louis-JeanS. Levetiracetam induced behavioral abnormalities in a patient with seizure disorder: A diagnostic challenge.Case Rep. Psychiatry202020201410.1155/2020/8883802 32908767
     [Google Scholar]
  2. Johannessen LandmarkC. PatsalosP.N. Drug interactions involving the new second- and third-generation antiepileptic drugs.Expert Rev. Neurother.201010111914010.1586/ern.09.136 20021326
     [Google Scholar]
  3. CoupezR. NicolasJ.M. BrowneT.R. Levetiracetam, a new antiepileptic agent: Lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.Epilepsia200344217117810.1046/j.1528‑1157.2003.25302.x 12558570
     [Google Scholar]
  4. Abou-KhalilB. Levetiracetam in the treatment of epilepsy.Neuropsychiatr. Dis. Treat.20084350752310.2147/NDT.S2937 18830435
     [Google Scholar]
  5. KamalrajR. SirisenaD. AmarasingheS.C. Levetiracetam induced behavioral changes: A case report.Sri Lanka J Psych,201892181910.4038/sljpsyc.v9i2.8188
     [Google Scholar]
  6. StrzelczykA. Schubert-BastS. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies.CNS Drugs202236101079111110.1007/s40263‑022‑00955‑9 36194365
     [Google Scholar]
  7. MajarwitzD. DvalishviliM. PastisI. Levetiracetam-induced psychosis in the setting of intracranial cavernomas.Case Rep. Psychiatry202220221410.1155/2022/9114118 35356150
     [Google Scholar]
  8. WittJ.A. HelmstaedterC. How can we overcome neuropsychological adverse effects of antiepileptic drugs?Expert Opin. Pharmacother.201718655155410.1080/14656566.2017.1309025 28303728
     [Google Scholar]
  9. BruntonL.L. Hilal-DandanR. Goodman & Gilman's: The pharmacological basis of therapeutics.13th edMcGraw-Hill Education2022
     [Google Scholar]
  10. HansenC.C. LjungH. BrodtkorbE. ReimersA. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: Focus on topiramate, levetiracetam, and perampanel.Behav. Neurol.2018201811810.1155/2018/2064027 30581496
     [Google Scholar]
  11. CampbellC. McCormackM. PatelS. A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.Epilepsia20226361563157010.1111/epi.17228 35298028
     [Google Scholar]
  12. CiruelasK. MarcotulliD. BajjaliehS.M. Synaptic vesicle protein 2: A multi-faceted regulator of secretion.In: InSeminars in cell & developmental biology.Academic Press20199513041
     [Google Scholar]
  13. CrowderK.M. GuntherJ.M. JonesT.A. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).Proc. Natl. Acad. Sci.19999626152681527310.1073/pnas.96.26.15268 10611374
     [Google Scholar]
  14. LöscherW. GillardM. SandsZ.A. KaminskiR.M. KlitgaardH. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond.CNS Drugs201630111055107710.1007/s40263‑016‑0384‑x 27752944
     [Google Scholar]
  15. MbizvoG.K. DixonP. HuttonJ.L. MarsonA.G. The adverse effects profile of levetiracetam in epilepsy: A more detailed look.Int. J. Neurosci.2014124962763410.3109/00207454.2013.866951 24256446
     [Google Scholar]
  16. ZakiS. Adverse drug reaction and causality assessment scales.Lung India201128215215310.4103/0970‑2113.80343 21712934
     [Google Scholar]
  17. HartwigS.C. SiegelJ. SchneiderP.J. Preventability and severity assessment in reporting adverse drug reactions.Am. J. Health Syst. Pharm.19924992229223210.1093/ajhp/49.9.2229 1524068
     [Google Scholar]
/content/journals/cds/10.2174/0115748863285429240326172920
Loading

  • Article Type:     Case Report
Keyword(s): antiepileptic drug; behavioural changes; Levetiracetam; neurological impact; psychiatric symptoms

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test